Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate

Benzinga · 3d ago
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(8.73) per share which missed the analyst consensus estimate of $(7.59) by 15.02 percent.